IL18 and cancer: Keeping these observations in view, several studies support the use of specific inhibitors, antagonists, and monoclonal antibodies against components of the inflammasome, e.g., caspase-1, IL-1β, and IL-18, as therapeutic approaches beneficial for controlling inflammation and improving cancer prognosis (238).